Yun-Fan Liaw

TL;DR: Continuous treatment with lamivudine delays clinical progression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis by significantly reducing the incidence of hepatic decompensation and the risk of hepatocellular carcinoma.

TL;DR: Among patients with HBeAg-positive chronic hepatitis B, the rates of therapeutic and histologic response at 1 year were significantly higher in patients treated with telbivudine than in patientstreated with lamivudines.

TL;DR: Treatment with lamivudine for 2 years is both well tolerated and efficacious in patients with chronic hepatitis B and the emergence of YMDD mutant continued to clear serum HBeAg and maintain lower median serum HBV-DNA and ALT levels than baseline values.

TL;DR: Measurements of HBV viral load and genotype may help to define which male HBV carriers aged 30 years or older are at high risk for HCC.

TL;DR: Recent molecular epidemiological studies have shown that low serum retinol levels as well as elevated serum levels of testosterone, neu oncoprotein and aflatoxin B1‐albumin adduct are associated with an increased HCC risk, and there is a synergistic interaction on HCC between chronic HBV infection and a flatoxin exposure.